Comparative Pharmacology
Head-to-head clinical analysis: APADAZ versus FYREMADEL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: APADAZ versus FYREMADEL.
APADAZ vs FYREMADEL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
APADAZ is a combination of benzhydrocodone, a prodrug of hydrocodone, and acetaminophen. Hydrocodone acts as a full mu-opioid receptor agonist, inhibiting ascending pain pathways and altering pain perception. Acetaminophen's mechanism involves inhibition of cyclooxygenase (COX) enzymes, particularly in the CNS, and modulation of serotonergic pathways, contributing to analgesia and antipyresis.
FYREMADEL is a GLP-1 receptor agonist that activates GLP-1 receptors, increasing insulin secretion and decreasing glucagon secretion in a glucose-dependent manner, and slows gastric emptying.
Each tablet contains benzhydrocodone 4.08 mg (hydrocodone 3.33 mg) and acetaminophen 325 mg. One to 2 tablets every 4 to 6 hours as needed for pain; maximum 12 tablets per 24 hours.
100 mg orally twice daily.
None Documented
None Documented
Terminal elimination half-life: 2-4 hours for benzhydrocodone; context: immediate-release, dosing every 4-6 hours.
Terminal half-life: 12 hours (range 8–16 h) in healthy adults; prolonged in hepatic impairment.
Renal: ~90% as conjugates, ~10% unchanged; fecal: minimal; enterohepatic recirculation occurs.
Renal: 60% unchanged; Biliary/Fecal: 30% as metabolites; 10% other.
Category C
Category C
Opioid Analgesic
Opioid Analgesic